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The effects of meldonium 
on the acute ischemia/reperfusion 
liver injury in rats
Siniša Đurašević1*, Maja Stojković2, Jelena Sopta2, Slađan Pavlović3, Slavica Borković‑Mitić3, 
Anđelija Ivanović3, Nebojša Jasnić1, Tomislav Tosti4, Saša Đurović5, Jelena Đorđević1 & 
Zoran Todorović2,6
Acute ischemia/reperfusion (I/R) liver injury is a clinical condition challenging to treat. Meldonium 
is an anti‑ischemic agent that shifts energy production from fatty acid oxidation to less oxygen‑
consuming glycolysis. Thus, we investigated the effects of a 4‑week meldonium pre‑treatment 
(300 mg/kg b.m./day) on the acute I/R liver injury in Wistar strain male rats. Our results showed that 
meldonium ameliorates I/R‑induced liver inflammation and injury, as confirmed by liver histology, 
and by attenuation of serum alanine‑ and aspartate aminotransferase activity, serum and liver 
high mobility group box 1 protein expression, and liver expression of Bax/Bcl2, haptoglobin, and 
the phosphorylated nuclear factor kappa‑light‑chain‑enhancer of activated B cells. Through the 
increased hepatic activation of the nuclear factor erythroid 2‑related factor 2, meldonium improves 
the antioxidative defence in the liver of animals subjected to I/R, as proved by an increase in serum 
and liver ascorbic/dehydroascorbic acid ratio, hepatic haem oxygenase 1 expression, glutathione 
and free thiol groups content, and hepatic copper‑zinc superoxide dismutase, manganese superoxide 
dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. Based on our results, 
it can be concluded that meldonium represent a protective agent against I/R‑induced liver injury, with 
a clinical significance in surgical procedures.
Acute ischemia/reperfusion (I/R) refers to a temporary abolishment of blood flow during surgical interventions, 
followed by its re-establishment once an intervention is  finished1. I/R damages affected tissue through numerous 
pathological processes, such as inflammation, oxidative stress, disturbance of cellular signalling pathways, and cell 
apoptosis and  necrosis2. The hepatic I/R molecular pathways begin with increased radical oxygen species (ROS) 
formation during the ischemic phase. Cellular damage induced by ROS causes a release of Damage-Associated 
Molecular Pattern Molecules (DAMPs), such as high mobility group Box 1 protein (HMGB1), which is known 
to induce inflammation by activating the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB 
p65)  pathway3. The resulting release of inflammatory cytokines and chemokines leads to the consequent activa-
tion of pro-inflammatory neutrophils, which further amplify the tissue  destruction4.
There are several possible therapeutic options for I/R liver injury, such as organ preservation, inhibition 
of ROS formation, or the modulation of immune system  activation5. While the organ preservation strategy 
showed the most promising  results6, the use of TNF  inhibitors7,  corticosteroids8, or free-radical scavengers 
such as N-acetyl  cysteine9, has been mostly unsuccessful, or with limited success. In our previous work in the 
model of renal I/R, we showed that meldonium, a clinical drug used to treat myocardial and cerebral ischemic 
 conditions10, exhibits anti-inflammatory  properties11. It inhibits synthesis and transport of carnitine, disturbing 
transport of cytosolic long-chain fatty acids (FAs) into mitochondria, and redirecting it to  peroxisomes12. In this 
way, meldonium protects mitochondria against the accumulation of toxic long-chain FAs  intermediates13, and 
shifts energy production to glycolysis, which is less oxygen-demanding in comparison with the FAs oxidation, 
and thus more favourable under ischemic conditions.
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For these reasons, the protective effect of a four-week meldonium pre-treatment in a dose of 300 mg/kg 
b.m./day was investigated in a model of rat hepatic I/R. This dose was chosen because it is similar to the clini-
cal human  use14,15, and within the range of previously studied animal doses of  meldonium16, where it proved 
to be both highly effective and safe. As a general marker of meldonium metabolic action, liver concentration of 
glucose, lactic acid, carnitine, FA, and glycerol were measured. The extent of liver injury was assessed by a tissue 
histology, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase 
(ALP) activity, NF-κB p65 activation by phosphorylation, and expression of NF-kB p65-regulated acute-phase 
protein haptoglobin (Hp). The ratio of Bax and Bcl-2 in the liver and the serum and liver HMGB1 levels were 
measured as the markers of apoptotic and necrotic cell death. The liver antioxidant defence was investigated by 
monitoring the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) by phosphorylation, and expres-
sion of Nrf2-regulated antioxidative enzyme haem oxygenase 1 (HO-1), and by measuring the activity of the 
copper-zinc superoxide dismutase (CuZnSOD), manganese superoxide dismutase (MnSOD), catalase (CAT), 
glutathione peroxidase (GSH-Px), glutathione reductase (GR), and glutathione S-transferase (GST), free sulfhy-
dryl groups (SH) and glutathione (GSH) concentration, and the level of lipid peroxidation (thiobarbituric acid 
reactive substances, TBARS). Ascorbic acid is a well-known effector of the antioxidative system, so our experi-
ment also included the determination of serum, adrenal gland, and liver ascorbic acid (AA) and dehydroascorbic 
acid (DHA) concentration. Since the link between ascorbic acid and catecholamine production in the adrenal 
glands is well  known17,18, we also determined the noradrenaline (NA) and adrenaline (AD) concentrations in 
the adrenal glands.
Results and discussion
Our finding that I/R increases hepatic lactic acid concentration for 50% (Table 1) suggests that, rather than 
oxidative phosphorylation meeting the ATP demand, glycolysis hastened ATP production at the substrate-level 
during I/R. In aerobic conditions, pyruvate, as the end product of glycolysis, enters the Krebs cycle avoiding 
the lactate  production19. However, under anaerobic conditions, as is the case with I/R, it is converted by lactate 
dehydrogenase to lactic  acid20. The fact that hepatic glucose content was unaffected by I/R (Table 1) is probably 
the result of the short I/R duration, and otherwise high liver glucose content.
Carnitine is essential for mitochondrial β-oxidation, since long-chain fatty acyl-CoA needs to be converted 
to fatty acyl-carnitine by carnitine palmitoyltransferase I for transport over the outer mitochondrial membrane, 
and further transport by the carnitine-acylcarnitine translocase across the inner membrane. Once inside the 
mitochondrial matrix, fatty acyl-carnitine is re-converted to fatty acyl-CoA by carnitine palmitoyltransferase II, 
becoming ready for the ATP production through β-oxidation. Thus, the I/R-induced decrease in liver triglycer-
ides content for 50%, along with the increase of hepatic glycerol, FAs, and carnitine concentration (Tables 1 and 
2) implicate an increase in liver lipolysis and FAs β oxidation. This is probably a compensatory reaction against 
impaired ATP production due to the substrate-level glycolysis, and the same effect has been described in the 
ischemic/reperfused  heart21,22.
Being a γ-butyrobetaine analogue, meldonium inhibits the activity of γ-butyrobetaine hydroxylase, the 
enzyme that catalyses the formation of l-carnitine23, and the l-carnitine renal re-absorption24. Our results 
show that meldonium decreases liver carnitine, glycerol, and FAs concentration in both sham and I/R groups of 
rats, and increases triglycerides content in I/R operated animals (Tables 1 and 2). In addition, the I/R-induced 
liver lactate concentration increase was reduced by meldonium for 30%, and that the same effect was observed 
in sham-operated animals (50% decrease in comparison to the S group). It should be noted that meldonium 
also decreases glucose content in sham and I/R operated animals (Table 1), which is consistent with the litera-
ture data showing an increase in glucose uptake and a decrease in the lactate concentration in the mouse heart 
treated with  meldonium25. In that sense, our results implicate that meldonium decreases liver lipolysis and FAs 
β oxidation, and stimulates aerobic oxidation of glucose as an oxygen-sparing mechanism for ATP production 
under ischemic conditions.
The restoration of normal oxygen level during reperfusion causes a release of cytokines and chemokines from 
activated tissue-resident macrophages and infiltration of pro-inflammatory  neutrophils26. By releasing oxidants 
and proteases, the recruited neutrophils damage hepatocytes and lead to the massive apoptotic and necrotic cell 
death  response27. It has been suggested that a delicate interplay between anti- and pro-apoptotic members of 
Table 1.  Liver carnitine (μg/g wet tissue mass), and glucose, lactic acid, triglycerides, and glycerol 
concentration (μg/mg wet tissue mass). Experimental group abbreviations: S sham-operated rat group, 
S + M sham-operated + meldonium rat group, I/R ischemia/reperfusion rat group, I/R + M ischemia/
reperfusion + meldonium rat group. The number of animals per experimental group: n = 8. The data are given 
as mean ± standard error of the mean. Minimal significant level: p < 0.05. Significantly different: ain respect to S 
group; bin respect to I/R group.
S S + M I/R I/R + M
Glucose 2.18 ± 0.11 1.19 ± 0.13a 2.23 ± 0.15 1.51 ± 0.18ab
Lactic acid 25.39 ± 0.83 14.46 ± 0.84a 36.97 ± 0.93a 25.71 ± 1.00b
Carnitine 149.20 ± 3.95 91.58 ± 4.55a 498.69 ± 11.96a 338.12 ± 16.72ab
Triglycerides 6.44 ± 0.09 6.04 ± 0.04 3.25 ± 0.10a 5.86 ± 0.03ab
Glycerol 0.049 ± 0.001 0.036 ± 0.001a 0.152 ± 0.002a 0.052 ± 0.001b
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the Bcl2 family of proteins is necessary for the repair of damaged cells after an ischemic  insult28, and that over-
expression of anti‐apoptotic Bcl2 can block both apoptosis and  necrosis29, and protect ischemic tissue against 
I/R-induced oxidative  stress30. Our finding that I/R increases the liver Bax/Bcl2 ratio for almost 50% and that 
meldonium reduces this increase by returning the value to the control level (Fig. 1A), points to the acceleration 
of pro-apoptotic events during I/R, and its effective reduction by meldonium.
Apoptosis is an energy-requiring process, so the impaired ATP production in I/R may cause failure in the 
apoptosis induction, and the development of necrosis followed by the uncontrolled release of DAMPs into the 
extracellular  space31. One of these molecules, the HMGB1, diffuses out of the stressed, damaged, or dying cells, 
which is why it serves as a necrotic  marker32. Our results show that I/R and meldonium change HMGB1 expres-
sion in a manner similar to Bax/Bcl2: while I/R increases the liver and serum levels of HMGB1 (twofold and 
20%, respectively), concurrent meldonium pre-treatment reduces it for 30% and 20%, respectively (Fig. 1A). 
The fact that I/R-induced HMGB1 release was more pronounced in the liver than in serum speaks of the tissue 
localisation of this process. This is important since HMGB1 further propagates inflammation upon release in 
serum by activating the NF-κB pathway through binding to TLR2, TLR4, TLR9, and the advanced glycation 
end products (RAGE) receptors of leukocytes or endothelial  cells33. It can be said that these results prove that 
meldonium protects not only against the I/R-induced necrosis but also  inflammation34.
Haptoglobin is the primary haemoglobin (Hb) binding plasma protein which attenuates the adverse effects 
of extracellular Hb. The cellular receptor of the Hb-Hp complex is the monocyte/macrophage CD163 scav-
enger receptor. After the binding to CD163, cellular internalisation of the complex leads to the effective Hb 
 neutralisation35. Based on our results, I/R causes a threefold increase in the liver Hp level, which concurrent 
meldonium treatment reduced back to the control level (Fig. 1B). Since the same effect was also present in sham-
operated animals (40% decrease in comparison to control group, Fig. 1B), it can be concluded that meldonium 
increases liver-adaptive responses to tissue injury through enhanced Hb sequestration and clearance.
Another factor that protects against tissue injury is HO-1, an enzyme that plays a vital role in the catabolism of 
 haem36. It has been shown that HO-1−/− knockdown mice develop the progressive inflammatory disease followed 
by a robust increase in pro-inflammatory  cytokines37, and that overexpression of HO-1 attenuates cellular damage 
and reduces apoptosis in the  liver38. The HO-1 promoter contains binding sites for various transcription factors, 
including phosphorylated  Nrf239. Our finding that I/R decreases hepatic levels of p-Nrf2 and HO-1 by about 40%, 
which concurrent meldonium pre-treatment increases for a fivefold and 20%, respectively (Fig. 1B,C), points 
to a new role of the Nrf2/HO-1 signalling pathway in meldonium protection against I/R-induced liver injury.
Initially identified as a DNA binding protein in activated B  cells40, the NF-κB modulates the gene expression 
in diverse cellular processes, such as stress responses to a variety of noxious stimuli, or cell proliferation and 
 apoptosis41. Accordingly, inflammatory signals activate NF-kB p65 by  phosphorylation42, causing its nuclear 
translocation and transactivation of target genes, including the gene for  Hp43. Our results show that I/R increases 
the hepatic expression of phosphorylated NF-κB p65 (Fig. 1C), which is in line with the literature data showing 
time-dependent activation of NF-κB p65 after the initiation of  reperfusion44. While in S + M group of animals 
meldonium does not change hepatic Nrf2 phosphorylation, in I/R + M group, there is a 2.5-fold increase (Fig. 1C). 
Thus, as a result of simultaneous NF-κB p65 and Nrf2 activation changes, the p-NF-κB p65/p-Nrf2 ratio remained 
unchanged in the S + M group, increased by 70% in the I/R group, and strongly decreased in the I/R + M group. 
These results point to a new hepatoprotective role of meldonium mediated through the p-NF-κB p65/p-Nrf2 
Table 2.  Hepatic fatty acids concentration (µg/mg tissue). Experimental group abbreviations: S sham-operated 
rat group, S + M sham-operated + meldonium rat group, I/R ischemia/reperfusion rat group, I/R + M ischemia/
reperfusion + meldonium rat group. The number of animals per experimental group: n = 8. The data are given 
as mean ± standard error of the mean. Minimal significant level: p < 0.05. Significantly different: ain respect to S 
group; bin respect to I/R group.
S S + M I/R I/R + M
C14:0 0.086 ± 0.007 0.030 ± 0.003a 0.125 ± 0.005a 0.067 ± 0.009b
C15:0 0.064 ± 0.003 0.037 ± 0.002a 0.152 ± 0.015a 0.072 ± 0.008b
C16:0 5.221 ± 0.155 2.114 ± 0.150a 10.585 ± 0.445a 4.766 ± 0.311b
C16:1 0.444 ± 0.021 0.149 ± 0.010a 0.631 ± 0.033a 0.262 ± 0.012ab
C17:0 0.312 ± 0.016 0.139 ± 0.007a 0.708 ± 0.034a 0.304 ± 0.020b
C17:1 0.039 ± 0.003 0.020 ± 0.001a 0.076 ± 0.006a 0.035 ± 0.003b
C18:0 5.160 ± 0.136 2.109 ± 0.102a 11.730 ± 0.477a 4.935 ± 0.239b
C18:1 cis 0.828 ± 0.041 0.364 ± 0.025a 1.717 ± 0.128a 0.899 ± 0.049b
C18:1 trans 2.121 ± 0.208 0.667 ± 0.038a 2.933 ± 0.114a 1.484 ± 0.149ab
C18:2 c + t 4.900 ± 0.217 1.895 ± 0.193a 9.482 ± 0.386a 4.301 ± 0.358b
C18:3 n3 0.054 ± 0.004 0.018 ± 0.001a 0.078 ± 0.005a 0.047 ± 0.002b
C20:1 0.019 ± 0.001 0.012 ± 0.001a 0.037 ± 0.005a 0.021 ± 0.001b
C20:2 0.117 ± 0.005 0.045 ± 0.003a 0.263 ± 0.015a 0.128 ± 0.006b
C20:3 n6 0.072 ± 0.003 0.029 ± 0.003a 0.156 ± 0.007a 0.050 ± 0.004ab
C20:3 n3 5.125 ± 0.083 2.406 ± 0.142a 12.578 ± 0.547a 5.455 ± 0.249b
C22:6 + C22:1 0.819 ± 0.029 0.393 ± 0.020a 1.766 ± 0.066a 0.827 ± 0.035b
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pathways interplay, in accordance with the literature data showing beneficial effects of NF-κB expression decrease 
in ischemic  liver45,46.
Figure 1.  Representative immunoblots of protein expression levels: (A) liver Bax/Bcl-2 ratio, and liver 
and serum HMGB1 expression; (B) liver Hp and HO-1 expression; and (C) liver p-Nrf2 and p-NF-κB p65 
expression, and p-NF-κB p65/p-Nrf2 ratio. β actin was used as a loading control. The blots cropped from 
different gels are delineated with the black line (see Supplementary Information). Experimental group 
abbreviations: S sham-operated rat group, S + M sham-operated + meldonium rat group, I/R ischemia/
reperfusion rat group, I/R + M ischemia/reperfusion + meldonium rat group. The number of animals per 
experimental group: n = 8. Data are given as mean ± standard error of the mean. Minimal significant level: 
p < 0.05. Significantly different: ain respect to S group; bin respect to I/R group.
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It is known that Nrf2 increases the expression of many antioxidative enzymes by binding to antioxidant 
response  elements47, such as CuZnSOD, MnSOD, GSH-Px, GST, and CAT 48, Nrf2 also controls the expression 
of the catalytic and the modifier subunits of the glutamate-cysteine ligase complex that catalyses the reaction of 
glutamate with cysteine, the rate-limiting step in the synthesis of  GSH49. Our results show that the p-Nrf2 expres-
sion decrease in I/R group (Fig. 1C) was followed by a 30%–50% decrease in hepatic CuZnSOD, MnSOD, and 
GSH-Px activity, and a 2.5-fold decrease in the liver GSH content (Table 3). Unexpectedly, despite the I/R-induced 
p-Nrf2 expression decrease, the CAT activity remained unchanged in comparison with the sham-operated con-
trols (Table 3). It is known that CAT activity in the liver is among the highest compared to other  tissues50, so it 
is possible that it is already high enough to meet the needs of I/R-induced increased oxidative stress completely. 
The observed rise in hepatic GST activity in animals from I/R group (Table 3) represents a way of antioxidative 
protection against lipid  hydroperoxides51, in agreement with the observed increase in the hepatic level of lipid 
peroxidation in the same group of animals (Table 3).
In I/R + M group, meldonium restores hepatic antioxidative defence mostly through reverse changes relative 
to those induced by I/R, i.e., through the CuZnSOD and MnSOD activity increases by 50%, the GSH-Px activity 
and GSH content increase 2.5-fold, and the GST activity decreases by 10% (Table 3). Unexpectedly, meldonium 
pre-treatment also doubled the CAT activity in comparison to the I/R group, probably because of a remarkable 
(fivefold) increase of p-Nrf2 expression (Fig. 1C). Due to its peroxisomal  location52, catalase is a common marker 
of the organelles number and  localisation53. Peroxisomes catalyse a broad range of substrates, mainly related to 
lipid metabolism. As we pointed earlier, meldonium redirects long-chain FAs transport to  peroxisomes12, thus 
increasing peroxisomal FAs oxidation and the peroxisomes density by FAs interaction with the peroxisome 
proliferator-activated receptor  alpha54. In this way, the observed increased of CAT activity in I/R + M group may 
reflect the changes in peroxisomes density, as a kind of molecular evidence of meldonium physiological effects.
It should be noted that an increase in hepatic MnSOD, CAT, and GSH observed in animals from S + M group 
(Table 3) was not linked to the Nrf2 expression level, which remained unchanged in comparison to the sham-
operated controls (Fig. 1C). The inhibitory effect of meldonium on the hepatic FAs oxidation could be a pos-
sible explanation, as presented in Tables 1 and 2. Main sites of the mitochondrial ROS production are electron 
transport chain Complexes I and III, whose electron-donating centres, once when they reach highly reduced 
state, enable an electrons “leak”, and consequent superoxide anion radical production. The redox status of those 
centres depends, among others, on the rate of chain electron flow, whose decrease leads to the centres higher 
reduced state, and thus increased oxidative  stress55. The catabolic intermediates and the by-product of long-chain 
FAs oxidation are known to slow-down the chain electron flow  rate56, and inhibit the activity of several matrix 
enzymes involved in maintenances of mitochondrial redox balance and mitigation of ROS  formation57. By redi-
recting long-chain FAs transport to peroxisomes, meldonium prevents the mitochondrial accumulation of these 
FAs  intermediates1,3 and reduces the mitochondrial ROS formation, whose ratio asymptotically increases with 
the FAs  length58. In this way, meldonium decreases the risk of long-chain FAs mediated mitochondrial oxidative 
stress by a mechanism that is Nrf2 independent.
Another proof that meldonium prevents I/R-induced oxidative stress are the changes in the level of lipid 
peroxidation and the thiol groups concentration (Table 3). The concentration of the SH groups can be considered 
as a degree of the cell reduced state, which is why its increase indicates reduced oxidative  stress59. The level of 
lipid peroxidation, on the other hand, can be considered as a general indicator of oxidative stress. Our results 
show that I/R, while not affecting the SH group concentration, increases the level of lipid peroxidation, which 
meldonium pre-treatment decreases (Table 3). In addition, meldonium also increases the SH concentration in 
the liver of both the I/R and sham-operated rats, confirming the antioxidative effect of meldonium.
Table 3.  The activities of liver copper-zinc superoxide dismutase (CuZnSOD, U/g tissue), manganese 
superoxide dismutase (MnSOD, U/g tissue), catalase (CAT, μmol  H2O2/min/g tissue), glutathione peroxidase 
(GSH-Px, μmol NADPH/min/g tissue), glutathione reductase (GR, nmol NADPH/min/g tissue) and 
glutathione S-transferase (GST, nmol GSH/min/g tissue), as well as liver concentrations of glutathione 
(GSH, nmol/g tissue), sulfhydryl groups (SH, nmol/g tissue), and lipid peroxides (TBARS, nmol/g tissue). 
Experimental group abbreviations: S sham-operated rat group, S + M sham-operated + meldonium rat group, 
I/R ischemia/reperfusion rat group, I/R + M ischemia/reperfusion + meldonium rat group. The number of 
animals per experimental group: n = 8. The data are given as mean ± standard error of the mean. Minimal 
significant level: p < 0.05. Significantly different: ain respect to S group; bin respect to I/R group.
S S + M I/R I/R + M
CuZnSOD 6352 ± 157 6113 ± 121 3548 ± 171a 5967 ± 133.164b
MnSOD 3358 ± 74 4599 ± 134a 1297 ± 48a 2014 ± 37ab
CAT 76,959 ± 2015 91,565 ± 2,706a 77,272 ± 2,723 147,865 ± 5,002ab
GSH-Px 72,172 ± 4408 74,382 ± 1,879 55,901 ± 3,113a 14,320 ± 4,243ab
GSH 4037 ± 241 6449 ± 209a 1513 ± 99a 3645 ± 95ab
GR 7852 ± 275 8135 ± 377 17,126 ± 397a 20,765 ± 654ab
GST 27,369 ± 6190 29,007 ± 4,983 37,262 ± 5,175a 33,139 ± 6,919ab
SH 4988 ± 192 6207 ± 260a 5076 ± 195 7499 ± 371ab
TBARS 1.242 ± 0.036 1.202 ± 0.035 1.400 ± 0.050a 1.180 ± 0.029b
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The ratio between AA and DHA is an important marker of tissue antioxidative defence. The redox reactions 
of vitamin C start with the single-electron oxidation of AA into mono-dehydroascorbate radical (MDHA), which 
further goes through the process of dismutation to DHA plus  AA60. Both MDHA and DHA are reduced back 
to ascorbate by several enzymatic systems in a process referred to as vitamin C  recycling61. For that reason, the 
decrease in AA/DHA ratio indicates the attenuation of tissue antioxidant defence and increased oxidative stress. 
In contrast, its increase indicates improved tissue antioxidant defence and decreased oxidative stress. Thus, the 
fact that I/R decreases hepatic AA/DHA ratio, increased by meldonium pre-treatment in both sham-operated and 
I/R animals (Table 4), confirms the role of I/R in promotion of oxidative stress, and its prevention by meldonium.
The changes in hepatic AA/DHA ratio were mapped to the serum (Table 4), as the major body depot of vita-
min C, which primarily depends on ascorbate synthesis in the  liver62. In contrast to liver and serum, in adrenal 
glands, the AA/DHA ratio was increased in all experimental groups (Table 4). While in S + M group it can be 
explained as a consequence of identical changes in liver and serum, in I/R and I/R + M groups, it is probably the 
result of impaired adrenal catecholamine synthesis. Ascorbic acid is an important cofactor for noradrenaline 
synthesis, during which it undergoes  oxidation17. Therefore, the decrease in NA synthesis and its further conver-
sion to AD may preserve ascorbic acid oxidation causing an AA/DHA ratio increase, in accordance with the data 
showing adrenal catecholamine decrease in animals from I/R and I/R + M groups (Table 4). However, it remains 
unclear why a sevenfold increase of NA in S + M rat group causes an even higher increase in the AA/DHA ratio 
in comparison to I/R and I/R groups.
As we discussed earlier, meldonium exerts its antioxidative effect through both p-Nrf2 dependent and inde-
pendent pathways. However, the role of meldonium in the regulation of nitric oxide (NO) production can also 
be considered as the way of meldonium antioxidative action. NO is produced by three isoforms of nitric oxide 
synthases (NOS): endothelial (eNOS), neuronal (nNOS), and inducible (iNOS). While many of NO functions are 
protective or anti-inflammatory, the role NO in I/R is considered to be  detrimental63. We did not measure iNOS 
expression nor NO concentration in this experiment, but it is to be expected that both will be increased in the 
I/R group as a result of the increased p-NF-κB p65 expression and decreased in the I/R + M group as a result of 
decreased p-NF-κB p65 expression (Fig. 2). Besides, it seems that meldonium can also lower NO tissue concentra-
tion by an unknown mechanism which does not depend on the NOS activity, nor the p-NF-κB p65  expression64.
Aspartate aminotransferase and alkaline phosphatase are enzymes present in a variety of tissues, including the 
liver, brain, pancreas, heart, kidneys, lungs, and skeletal  muscles65. Consequently, if any of these tissues are dam-
aged, AST and ALP will be released into the bloodstream. Our results showed that I/R causes 16-fold increases 
in ALT and AST, and a 1.6-fold increase in ALP activity (Table 5), following the literature data showing that 
I/R causes a much greater increase in serum ALT and AST activity than in  ALP66. While in the sham-operated 
animals meldonium decreases the activity of all three enzymes, in the I/R animals, it lowers activity only of ALT. 
An explanation could be the fact that ALT, with the highest activity in hepatocytes and low in other tissues, 
represents a much better marker of hepatocellular injury than AST or ALP, which share similar activity between 
liver and numerous non-hepatic tissues.
Experimental group abbreviations: S sham-operated rat group, S + M sham-operated + meldonium rat group, 
I/R ischemia/reperfusion rat group, I/R + M ischemia/reperfusion + meldonium rat group.
Based on the result of liver histology analysis, it can be concluded that in sham-operated animals meldonium 
worsens the histological profile of the liver, the proof of which is the higher Suzuki histological score of samples 
from the S + M group in comparison to samples from the S group (Table 6). While samples from the S group 
show mild to moderate disorganisation of the hepatic cords, intensive interstitial oedema, mild erythrocytic 
extravasation into sinusoidal spaces (yellow arrow), intensive and diffuse parenchymal vacuolisation with the 
irregular nuclear contours, chromatin condensation, pyknosis, and nuclear dust in many hepatocytes, and a 
lack of presence of binuclear hepatocytes (red arrow) (Fig. 2A), samples from the S + M group show an intensive 
hepatic cords disorganisation associated with marked interstitial oedema, diffuse and pronounced cytoplas-
matic vacuolisation in the form of microvascular degeneration (black arrow), regular nuclei with no evidence 
of chromatin condensation, pyknosis, nuclear dust, and focally presented binuclear hepatocytes (red arrow) 
(Fig. 2B). Although vacuolar degeneration seen in S + M group represents an unspecific marker of liver injury, a 
possible role of the meldonium liver biotransformation as a potential cause of it can be  discussed15. However, it 
should be stressed that more prominent and intense cytoplasmic changes in the S + M group are still reversible, 
Table 4.  The ascorbic/dehydroascorbic acid ratio (AA/DHA, % of sham) in the serum, liver, and adrenal 
glands, and adrenal noradrenaline and adrenaline content (µg/mg tissue). Experimental group abbreviations: 
S sham-operated rat group, S + M sham-operated + meldonium rat group, I/R ischemia/reperfusion rat group, 
I/R + M ischemia/reperfusion + meldonium rat group. The number of animals per experimental group: n = 8. 
The data are given as mean ± standard error of the mean. Minimal significant level: p < 0.05. Significantly 
different: ain respect to S group; bin respect to I/R group.
S S + M I/R I/R + M
Liver 100.00 ± 4.58 185.80 ± 10.42a 57.67 ± 4.42a 139.39 ± 7.04ab
Serum 100.00 ± 4.44 197.26 ± 17.02a 24.22 ± 2.67a 50.25 ± 2.17ab
Adrenal 100.00 ± 12.87 290.09 ± 19.38a 187.09 ± 13.74a 176.34 ± 8.46a
Noradrenaline 0.340 ± 0.011 2.185 ± 0.105a 0.098 ± 0.014a 0.088 ± 0.013a
Adrenaline 1.244 ± 0.048 1.068 ± 0.061 0.789 ± 0.076a 0.617 ± 0.058a
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Figure 2.  Liver histology analysis (H&E stain, 40 ×). Experimental group abbreviations: (A) sham-operated 
(S) rat group, (B) sham-operated + meldonium (S + M) group, (C) ischemia/reperfusion (I/R) rat group, 
(D) ischemia/reperfusion + meldonium (I/R + M) rat group. Yellow arrow—erythrocytic extravasation into 
sinusoidal spaces; black arrow—vacuolar degeneration; red arrow—binuclear hepatocytes.
Table 5.  The serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline 
phosphatase (ALP) activities (IU/L). Experimental group abbreviations: S sham-operated rat group, 
S + M sham-operated + meldonium rat group, I/R ischemia/reperfusion rat group, I/R + M ischemia/
reperfusion + meldonium rat group. The number of animals per experimental group: n = 8. The data are given 
as mean ± standard error of the mean. Minimal significant level: p < 0.05. Significantly different: ain respect to S 
group; bin respect to I/R group.
S S + M I/R I/R + M
ALT 46.33 ± 2.49 30.25 ± 1.05a 775.21 ± 51.47a 546.75 ± 31.77ab
AST 76.17 ± 4.05 62.60 ± 2.59a 1,311.00 ± 184.36a 1,107.36 ± 99.67a
ALP 71.83 ± 3.09 49.40.25 ± 3.33a 116.50 ± 10.50a 112.00 ± 8.83a
Table 6.  Liver Suzuki histological score (0–4) based on the sinusoidal congestion, vacuolization of 
hepatocyte cytoplasm, and parenchymal necrosis. Experimental group abbreviations: S sham-operated rat 
group, S + M sham-operated + meldonium rat group, I/R ischemia/reperfusion rat group, I/R + M ischemia/
reperfusion + meldonium rat group.
Congestion Vacuolization Necrosis Score
S Moderate Moderate ≤ 30% 3
S + M Severe Severe ≤ 60% 4
I/R Mild Mild ≤ 30% 2
I/R + M Mild Minimal Single cells 1
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without nuclear damage, in contrast to histological changes in samples from S group which indicate cell damage 
without  regeneration67.
By comparing the samples from the I/R and I/R + M groups, it can be concluded that the prevalence and 
intensity of liver regeneration is significantly higher in the animals pre-treated with  meldonium68, proved with 
the lower Suzuki histological score in samples from the I/R + M group in comparison to samples from the I/R 
group (Table 6). The samples from the I/R + M group show mild interstitial oedema and moderate microhemor-
rhages, rare focal hepatocytes vacuolisation, microvesicular degeneration, many binuclear hepatocytes as a sign 
of reparation (red arrow), and very rare hepatocytes with paler nuclei and cytoplasmatic granulation (Fig. 2D), in 
contrast to the samples from the I/R group which show mild disorganisation of hepatic cords, followed by mild 
interstitial oedema, focal erythrocytic extravasation into cystic sinusoidal spaces (yellow arrow), hepatocytes 
enlargement with focal cytoplasmatic vacuolisation localised around micro-bleedings (black arrow), pyknotic 
nuclei and chromatin condensation as a sign of necrosis, and diffusely presented binuclear hepatocytes (red 
arrow) (Fig. 2C).
Conclusions
The main effects of meldonium and I/R in our experiment are summarised in Fig. 3. According to the presented 
results, it can be concluded that meldonium protects the liver against I/R-induced injury in many aspects, includ-
ing anti-apoptotic, anti-necrotic, anti-inflammatory, and antioxidative. Some of these effects are the result of the 
observed changes in p-Nrf2 expression level, while others could be explained by meldonium-caused inhibition of 
long-chain fatty acids β oxidation and shift of energy production to glycolysis. Although it remains to be tested 
in clinical trials, the use of meldonium in preoperative management of patients subjected to surgical resection 
or liver transplantation represents an entirely new therapeutic approach in this field. This is especially true in 
relation to the efficacy of pre-treatment as the therapeutic approach since the use of drugs once when an injury 
occurs quickly reaches the viability threshold limit. Having all in mind, it can be concluded that meldonium 
might represent a protective agent against I/R-induced liver injury, with a clinical significance.
Materials and methods
Animals and treatments. The experiment was performed in accordance with the Directive 2010/63/EU 
of the European Parliament. Upon request of the National legislation, animal procedures were approved by the 
Veterinary Directorate of the Ministry of Agriculture, Forestry and Water Management, License number 323-
07-07137/2018-05.
Figure 3.  The summarised effects of meldonium pre-treatment on the liver ischemia/reperfusion. Meldonium 
pre-treatment improves the antioxidative defence through the increased hepatic activation of the nuclear factor 
erythroid 2-related factor 2 (p-Nrf2) and consequently hepatic haem oxygenase 1 (HO-1) expression, and 
activity of endogenous antioxidant enzymes. Thereby inhibits oxidative burst, tissue injury and cell necrosis, 
manifested by decreased expression of serum and liver high mobility group box 1 (HMGB1). Meldonium also 
reduces inflammatory cascade, as evident by decreased activation of the nuclear factor kappa-light-chain-
enhancer of activated B cells (p-NF-kB p65) by phosphorylation along with decreased haptoglobin (Hp) 
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Thirty-two male adult Wistar rats, with the average weight of 352.73 ± 4.08 g, were randomly divided into 
four groups with eight animals per group (i.e. sample size per group: n = 8 animals). Animals were housed two 
per cage and kept on the temperature of 22 ± 1 °C under 12-h light/dark regime. The experiment lasted for four 
weeks, with ad libitum access to standard rat food (Veterinary Institute, Subotica, Serbia), and tap water with or 
without dissolved meldonium. Animals were divided into groups as follows: sham-operated animals that drunk 
water without meldonium for four weeks before the surgical procedure (S group); sham-operated animals that 
drunk water with meldonium for four weeks before to surgical procedure (S + M group); I/R-operated animals 
that drunk water without meldonium for four weeks before the surgical procedure (I/R group); and I/R-operated 
animals that drunk water with meldonium for four weeks before the surgical procedure (I/R + M group).
Meldonium (Shenzhen Calson Bio-Tech Co., Ltd., China) concentration in water was adjusted weekly to 
achieve daily animals’ consumption of around 300 mg/kg b.m. Based on the whole experiment data, the average 
meldonium consumption was 304.29 ± 3.18 mg/kg b.m./day in S + M group, and 298.36 ± 4.11 mg/kg b.m./day 
in I/R + M group of animals.
Operative procedures. The model of partial liver I/R with 60 min of ischemia, followed by 4 h of reperfu-
sion was performed using a previously described  protocol69. Rats fasted for 16 h preceding the operation but 
were provided access to drinking water. The rats were anaesthetised with an intraperitoneal injection of 120 mg/
kg sodium thiopental (Thiopental, Nycomed Pharma GmbH, Unterschleissheim, Germany) and placed supinely 
on a heating pad (37.5 ± 1 °C). The saline infusion was provided during the whole experiment (8 ml/kg/h before 
reperfusion, and 2 ml/kg/h during reperfusion), and anaesthesia was maintained by sodium thiopental (10 mg/
kg, i.v.). After achieving surgical anaesthesia, the abdominal wall was opened, and porta hepatis and the portal 
triad (portal vein, hepatic artery, and biliary duct) identified. An atraumatic clamp was placed distal to the 
branch for the right lobe and used to prevent blood supply to the left, median, and caudate lobes of the liver. 
Occlusion was verified visually by the change in liver colour to a paler shade and upon reperfusion to a blush. 
After 60 min of ischemia, the clamp was removed, and the liver was subjected to reperfusion. At the end of the 
reperfusion period, anaesthetised rats were euthanised by cervical dislocation. Sham-operated rats underwent 
the same protocol without vascular occlusion.
Tissue sampling. Immediately after the euthanasia, blood was collected, serum  prepared70, and stored at 
− 80 °C until the analysis. The liver and adrenals were isolated and dissected out within 3 min, placed in ice-cold 
155 mmol NaCl, and washed with the same solution. One part of the liver was placed in formaldehyde for fur-
ther histological analysis. The tissue samples for the rest of the analysis were stored at − 80 °C until the analysis.
Biochemical analysis. The lactic acid, carnitine, L-ascorbic acid, phosphoric acid, meta-phosphoric acid 
(MPA), sodium phosphate monobasic dihydrate, dithiothreitol (DTT), ethylene glycol tetra-acetic acid (EGTA), 
DL-Noradrenaline hydrochloride (NA), perchloric acid and magnesium chloride  (MgCl2 × 5H2O) were pur-
chased from Sigma Aldrich. The glucose was purchased from Tokyo Chemical Industry (TCI Europe, Belgium). 
The glycerol was included in Sugar Alcohols Kit by Supelco (Sigma Aldrich). Potassium hydroxide, sodium 
hydroxide, sodium acetate trihydrate, and acetonitrile were purchased from Merck (Darmstadt, Germany). 
Ammonium formate was supplied by Fisher Scientific, formic acid (49–51%) by Fluka Analytical, and methanol 
by J.T. Baker. All chemicals were of an analytical grade of purity. Ultra-pure water was obtained via a Blue-
ClearRO600P reverse osmosis system with integrated BlueSoft07-MB mixed bed salt remover (Euro-Clear Ltd., 
Hungary).
Tissue samples (50 mg) were pulverised in a tissue grinder with 2 ml of ultra-pure deionised water. After 
the extraction at 0 °C in the ultrasound bath, the samples were centrifuged at 12,000 rpm. The supernatant was 
transferred in a standard flask and diluted with ultra-pure water to the 10 ml mark. The sample solutions were 
kept at − 80 °C until analysis. The concentration of lactic acid, glucose, carnitine, glycerol, and fatty acids was 
determined as described  earlier11,71.
The quantification of lactic acid, glucose, and glycerol was done by ion chromatography, using Dionex ICS-
3000 chromatographic system and IonPac AS15 Analytical, 4 × 250 mm (P/N 053940), and IonPac AG15 Guard, 
4 × 50 mm (P/N 053942) separation columns in case of lactic acid, and the CarboPac PA100 pellicular anion-
exchange column (4 × 250 mm) in case of glucose and glycerol (Dionex, Sunnyvale, CA, USA). The detection 
was performed using a gold electrode as the working, and an Ag/AgCl as the reference electrode.
For the lactic acid, a mobile phase flow rate was set at 1 ml/min, with the following gradient: 0–15 min: 10 mM 
KOH; 15–25 min: 10–45 mM KOH; 25–26 min: 45 mM KOH; 26–31 min: 45–10 mM KOH; and 31–36 min: 
10 mM KOH.
For the glucose, a mobile phase flow rate was set at 0.7 ml/min, with the following gradient: 0–5 min: 15% A, 
85% C; 5.0–5.1 min: 15% A, 2% B, 83% C; 5.1–12 min: 15% A, 2% B, 83% C; 12–12.1 min: 15% A, 4% B, 81% C; 
12.1–20 min: 15% A, 4% B, 81% C; 20–20.1 min: 20% A, 20% B, 60% C; and 20.1–30 min: 20% A, 20% B 60% C 
(were A represents 600 mM sodium hydroxide, B 600 mM sodium acetate, and C ultrapure water).
For the glycerol, a mobile phase flow rate was set at 0.5 ml/min, with the following gradient: 0.0–10 min: 10% 
A; 10.0–15.0 min: 10%–50% A; 15.0–15.1 min: 50%–80% A; and 15.1–20.0 80% A (were A represents 100 mM 
NaOH).
The quantification of carnitine was done by thin-layer chromatography, using CAMAG chromatographic 
chamber and Linomat 5 plates (Camag, Switzerland), RP-18 silica (Art. 5559, Merck, Germany), and acetoni-
trile–water binary mixture (1:1 v/v). The plates were scanned by CAMAG TLC Scanner 3 at 260 nm.
The quantification of triglycerides was done by planar chromatography. The 2 µl of lipid extract was applied 
to the 20 × 10 cm HPTLC silica gel plates (Art. 105641, Merck) as 6 mm band by using Automatic TLC sampler 4 
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(ATS4, Camag, Switzerland). Development of the plates was performed in CAMAG twin trough chamber using 
4 mobile phases:chloroform:methanol:acetic acid (90:10:1, v/v/v) up to 25 mm, n-hexane:diethyl-ether:acetone 
(60:40:5, v/v/v) up to 70 mm, n-hexane:diethyl-ether up to 85 mm, and 100% n-hexane up to 90 mm. For deri-
vatisation, the mixture of concentrate sulphuric acid and methanol (1:9, v/v) was used. Derivatised plates were 
heated at 110 °C on TLC Plate Heater III (Camag, Switzerland) until chromatographic zones become visible, 
followed by scanning in CAMAG TLC scanner 3 equipped with Linomat 4.
The FAs were extracted from the tissue by Folich modified  method72. The analysis was performed on Focus GC 
coupled with the PolarisQ mass spectrometer (Thermo Fisher, USA), using helium (1 ml/min) as the carrier gas. 
The oven temperature program was as follows: the initial temperature 50 °C (1 min), then 25 °C/min to 200 °C, 
and immediately 3 °C/min to 230 °C (held for 18 min). The injector was in split mode (50:1), while the injector, 
transfer line, and ion source temperatures were 250 °C, 260 °C and 260 °C, respectively. It was investigated the 
concentration of 18 fatty acids: myristic (tetradecanoic, C14:0), pentadecylic (pentadecanoic, C15:0), palmitic 
(hexadecanoic, C16:0), palmitoleic (cis-Δ9 hexadecenoic, C16:1), margaric (heptadecanoic, C17:0), heptadece-
noic acid (cis-Δ10 heptadecenoic acid, C17:1), stearic (octadiecanoic, C18:0), oleic/elaidic (cis- and trans-Δ9 
octadecenoic, C18:1), linoleic/linolelaidic (cis- and trans-Δ9,12 octadecenoic, C18:2 c + t), linolenic (cis- and 
trans-Δ9,12,15 octadecadienoic, C18:3) gondoic acid (cis-11 eicosenoic acid C20:1), eicosadienoic (cis-11,14 
eicosadienoic acid, C20:2), dihomo-γ-linolenic (cis-Δ8,11,14 eicosatrienoic acid, C20:3) dihomo-α-linolenic 
(cis,cis,cis-Δ11,14,17 eicosetrienoic, c20:3), behenic (docosanoic, C22:0), cervonic (cis,cis-Δ13,16 docosadienoic, 
C22:1), and euric (cis,cis,cis,cis,cis,cis-Δ4,7,10,13,16,19 docosahexaenoic, C22:6). Under applied chromatographic 
conditions, cervonic and euric acids coelute at the same retention time, so their concentrations were calculated 
as the sum. The same was the case for cis- and trans- forms of C18:2, so that the results were actually presented 
as the 16 fatty acids analysis.
The serum, liver, and adrenal concentration of AA and DHA was measured according to the method of 
Nováková et al.73. The tissue samples were homogenised by Ultra-Turrax homogeniser (IKA, China) in 10% 
MPA (1 mg:10 µl), and sonicated 3 times for 10 s. Serum samples were mixed with 10% MPA. Samples were 
centrifuged for 30 min at 18,000 rpm (4 °C), and the obtained supernatants were used for the analysis of native 
AA concentration. Total vitamin C concentration was analysed by converting sample DHA to AA with the 300 
µL DTT solution in phosphate buffer (30 min. at 4 °C) and using 10% MPA for the re-acidification of samples. 
The data were obtained by UltiMate 3000 HPLC system, using Acclaim Polar Advantage II, C18 (3 µm) HPLC 
column, and the RS electrochemical detector with the glassy carbon working electrode (Thermo Fisher, USA). 
The mobile phase (160 mM phosphate buffer, pH 3.0) was pumped for 10 min in an isocratic flow of 800 µl/min. 
The applied potential was 600 mV, and the separation temperature was 25 °C.
The concentration of adrenaline (AD) and noradrenaline (NA) was performed according to the method of 
Stefanovic et al.74 The catecholamines stock standard (1 mg/ml of methanol) was diluted by DEPROT solution 
(2% EGTA; 0.1 N  HClO4; 0.2%  MgCl2) in order to get the working standard. Adrenal glands were homogenised 
by Ultra-Turrax homogeniser (IKA, China) in DEPROT (1 mg:10 µl), and sonicated 3 times for 10 s. The data 
were obtained using the same HPLC system like the one described in the case of vitamin C determination. The 
mobile phase (100 mM ammonium formate as an A solution, and the methanol as a B solution) was pumped at 
a flow rate of 500 µl/min with the following gradient: 98% A and 2% B solution mix was used for the run, then 
B solution rose to reach 80% in the  13th minute starting from the minute 9, and the column was re-equilibrated 
with the initial mixture of mobile phase solutions (2% of A and 98% of B solution) starting from the 18th minute 
until the end of the run (25th min.). The applied potential was 850 mV, and the separation temperature was 25 °C.
Activities of ALT, AST and AP in serum were measured by Roche Cobas C501 Chemistry analyser, using 
ALTL, ASTL, and ALP2L reagent cassette (Roche Diagnostics, F. Hoffmann-La Roche Ltd, Switzerland).
The determination of liver oxidative stress biomarkers. All chemicals were purchased from Sigma 
Aldrich. The liver samples were minced and homogenised in 10 volumes of 25  mmol/l sucrose containing 
10 mmol/l Tris–HCl, pH 7.5 at 1,500 rpm using Ultra-Turrax homogeniser (IKA-Werke, Staufen, Germany) at 
4 °C. Homogenates were centrifuged at 4 °C at 100,000×g for 90 min, sonicated for 30 s at 10 kHz on ice (Ban-
deline Sonopuls HD 2070), and centrifugated in a Beckman ultracentrifuge at 100,000×g for 90 min at 4 °C.
Enzyme activity in the supernatant samples was measured in triplicates using Shimadzu UV-1800 spectro-
photometer and a temperature-controlled cuvette holder. Total SOD activity was measured by the method based 
on the capacity of SOD to inhibit the autoxidation of adrenaline to  adrenochrome75, and the same method was 
applied for the MnSOD measurement after pre-incubation with 8 mmol/l  KCN76. CAT activity was measured as 
the rate of the  H2O2 decomposition at 240 nm77. GSH-Px activity was determined by measuring the oxidation 
of nicotinamide adenine dinucleotide phosphate (NADPH) with t-butyl hydroperoxide at 340 nm78. GR activity 
was determined by measuring NADPH oxidation at 340 nm in the presence of  GSSG79.
GST activity was measured at 340 nm in a 100 mM tris buffer (pH 7.4), 1 mM GSH and tissue homogenate 
reaction mixture, using 1-chloro-2,4-dinitrobenzene as a  substrate80. GSH content was measured by the method 
based on the enzymatic cycling of the GSSG to GSH by GR and NADPH, using 2-vinylpyridine as the GSH 
masking  agent81. SH groups concentration was measured as the 5-thio-2-nitrobenzoic acid absorption at 412 nm, 
resulting from the 5,5′-dithiobis-(2-nitrobenzoic) acid reduction by free thiol  groups82. The lipid peroxides con-
centration was measured as the absorbance change at 532 nm in the reaction of sample malondialdehyde with 
the thiobarbituric acid as the  reagent83.
Western immunoblot analysis. The serum samples and liver homogenates (previously prepared for 
determination of oxidative stress biomarkers) were separated by 12% SDS-PAGE and transferred onto polyvi-
nylidene difluoride membranes (Hybond-P, Amersham Pharmacia Biotech), blocked in a 0.2% Tween 20, 50 mM 
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Tris HCl pH 7.6, and 150 mM NaCl solution containing 5% non-fat condensed milk. After the protein transfer, 
membranes were incubated for an hour and a half at room temperature with the following primary antibodies: 
Cell Signalling Technology rabbit polyclonal Bax (2772) and Bcl-2 (2876); Abcam rabbit polyclonal HMGB1 
(ab 18256), Hp (ab 131236), HO-1 (ab 13243), phospho-NF-κB p65 (Ser 311, ab 194926) and β-actin (ab 8227) 
antibodies; and the Thermo Fisher Scientific: rabbit polyclonal phospho-Nrf2 (Ser 40, PA5-67520) antibody. The 
blots were probed/re-probed with Abcam horseradish peroxidase-conjugated secondary (goat anti-rabbit IgG) 
antibodies (ab 205718, ab 97051). Immunoreactive bands were identified by an enhanced chemiluminescence 
detection system (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and the signals intensities were quantified 
using TotalLab (Phoretix, Newcastle Upon Tyne, England) electrophoresis software (ver.1.10). Actin was used as 
a loading control for the quantification.
Histology analysis. Liver samples were fixated in a 4% formaldehyde, dehydrated in an increasing series 
of ethanol solutions (70%, 96%, and 100%), and immersed in xylene. After being embedded into paraffin wax, 
samples were cut into 5 µm thick sections and stained with haematoxylin and eosin (H&E stain). Using the Leica 
DM LS 2 type 11020518016 microscope (Leica, Wentzler, Germany), a minimum of 10 fields of each liver section 
were analysed. The analysis evaluated tissue organisation, trabecular arrangement, sinusoidal changes, cytoplas-
matic vacuolisation, nuclear characteristics, and presence of binuclear cells. A Suzuki histological score was used 
for blind scoring by pathologist. According to sinusoidal congestion, vacuolization of hepatocyte cytoplasm, and 
parenchymal necrosis, sections were scored from 0 to  484.
Statistical analysis. The normality of data was checked with the Kolmogorov–Smirnov test. The differ-
ences between the groups were analysed through one-way ANOVA. When significant differences (p < 0.05) were 
found, Holm–Sidak post hoc test was performed for pairwise comparisons. All analyses and graphs were carried 
out in statistical package SIGMAPLOT, with the data presented as the mean ± standard error of the mean.
Ethical statement. The authors are accountable for all aspects of the work ensuring that questions related 
to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
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